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A disintegrin and metalloprotease with thrombospondin motifs 13
(ADAMTS13) is a metalloprotease that regulates von Willebrand
factor (VWF) function. ADAMTS13-mediated proteolysis is deter-
mined by conformational changes in VWF, but also may depend on
its own conformational activation. Kinetic analysis of WT ADAMTS13
revealed ∼2.5-fold reduced activity compared with ADAMTS13 lacking
its C-terminal tail (MDTCS) or its CUB1-2 domains (WTΔCUB1-2),
suggesting that the CUB domains naturally limit ADAMTS13 func-
tion. Consistent with this suggestion, WT ADAMTS13 activity was
enhanced ∼2.5-fold by preincubation with either an anti-CUB mAb
(20E9) or VWF D4CK (the natural binding partner for the CUB
domains). Furthermore, the isolated CUB1-2 domains not only bound
MDTCS, but also inhibited activity by up to 2.5-fold. Interestingly,
a gain-of-function (GoF) ADAMTS13 spacer domain variant (R568K/
F592Y/R660K/Y661F/Y665F) was ∼2.5-fold more active than WT
ADAMTS13, but could not be further activated by 20E9mAb or VWF
D4CK and was unable to bind or to be inhibited by the CUB1-2
domains, suggesting that the inhibitory effects of the CUB domains
involve an interaction with the spacer domain that is disrupted in
GoF ADAMTS13. Electron microscopy demonstrated a “closed” con-
formation of WT ADAMTS13 and suggested a more “open” confor-
mation for GoF ADAMTS13. The cryptic spacer domain epitope
revealed by conformational unfolding also represents the core an-
tigenic target for autoantibodies in thrombotic thrombocytopenic
purpura. We propose that ADAMTS13 circulates in a closed confor-
mation, which is maintained by a CUB–spacer domain binding inter-
action. ADAMTS13 becomes conformationally activated on demand
through interaction of its C-terminal CUB domains with VWF, mak-
ing it susceptible to immune recognition.
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Von Willebrand factor (VWF) is a large, multidomain glyco-protein that recognizes vascular damage by binding to ex-
posed collagen through its A3 domain (1–3). VWF tethered to
collagen responds to shear forces by adapting its conformation (4).
Under conditions of low shear, it is thought to adopt a globular
conformation, whereas at high shear, it unfolds and reveals its
binding site for the platelet GpIbα receptor on its A1 domain,
thereby facilitating platelet recruitment to the site of vascular injury.
VWF is stored before release into the plasma as multimers that
can be as large as 20–40 mers (5–8). On release from the cell, the
highest molecular weight multimers are the most hemostatically
active. Indeed, “ultra-large” multimers present a potential hazard
if their function is unregulated, because they can predispose to the
formation of VWF-platelet microthrombi that can occlude small
blood vessels, resulting in thrombotic thrombocytopenic purpura
(TTP) (9).
The metalloprotease ADAMTS13 is able to cleave the VWFA2
domain, dramatically reducing the multimeric size of VWF and
its propensity to form platelet microthrombi (10, 11). Cleavage of
VWF by ADAMTS13 is a multistep process. An initial positioning
interaction occurs between the D4CK domains of globular VWF
and ADAMTS13 (12, 13). As unfolding occurs, exposure of the
VWF scissile bond, Y1605-M1606, within the A2 domain is con-
trolled by structural elements contained within this domain (14–17).
Progressive unfolding allows distinct functional exosites within its
A2 domain to be exposed and engaged by complementary binding
sites on the protease, spacer, and disintegrin-like domains of
ADAMTS13 (18–22). Ultimately, docking of VWF scissile bond
P1′, P1, and P3 residues into subsites on the protease position the
scissile bond for cleavage (23). Thus, conformational changes in
VWF are essential for its efficient cleavage by ADAMTS13.
To explore the possible role of conformation on ADAMTS13
function (24, 25), we studied a recently described gain-of-function
(GoF) variant of ADAMTS13 (26). Jian et al. (26) concluded that
an ADAMTS13 GoF variant comprising composite spacer do-
main substitutions R568K/F592Y/R660K/Y661F/Y665F (here-
inafter, GoF) had an approximate fourfold increased ability to
cleave VWF substrates. A similar increase in activity on removal
of the C-terminal domains from ADAMTS13 has been reported
by others (27). Based on our investigation of the properties
of ADAMTS13, the GoF variant, and their derivatives reported
herein, we propose that ADAMTS13 normally adopts a globular
conformation determined by interaction of its spacer and CUB
domains and is unfolded during conformational activation.
Results
Increased Substrate Recognition Leads to Hyperactivity in GoF
ADAMTS13. Our kinetic analysis of VWF115 cleavage suggested
an approximate twofold difference between WT ADAMTS13
and the GoF variant (26) (Fig. 1A and kcat/Km values in Table 1).
There was no difference in kcat values, however, with the en-
hanced activity instead related to an increased affinity for the
substrate, as demonstrated by the Km values of 1.54 μM for WT
and 0.86 μM for GoF ADAMTS13. The KD(APP) values de-
termined by equilibrium plate binding assays suggest a twofold
increased affinity of GoF ADAMTS13 for VWF (Fig. 1B). This
finding was confirmed by both steady-state and global fit surface
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plasmon resonance (SPR) analysis (Fig. 1 C–E) and found to
be related to an approximate twofold increase in association
rate (Table 1).
Disruption of C-Terminal Interactions Activates WT ADAMTS13. We
hypothesized that initial VWF binding causes a conformational
activation of ADAMTS13 that may be unnecessary in the GoF
variant. Addition of the VWF D4CK domain fragment to WT
ADAMTS13 in a FRETS-VWF73 assay increased its activity
(normalized against that of WT ADAMTS13) in a dose-dependent
manner, resulting in a 2- to 2.5-fold increase (Fig. 2A). This hy-
peractivity was similar to that exhibited by GoF ADAMTS13.
Furthermore, the activity of GoF ADAMTS13 was not then en-
hanced by the addition of VWF D4CK (Fig. 2 B and C).
The 20E9 mAb recognizes the CUB2 domain of ADAMTS13.
Enhanced activity was observed on addition of the 20E9 mAb to
WT ADAMTS13 (Fig. 2D), reaching a maximum 2.5-fold en-
hanced activity. GoF ADAMTS13 was unaffected by the antibody
(Fig. 2 E and F), suggesting that the CUB domains may play an
important role in ADAMTS13 activation.
Regulation of ADAMTS13 Activity by the CUB Domains. We hy-
pothesized that the C-terminal CUB domains interact with the
spacer domain in the native WT ADAMTS13. We predicted that
removal of the C-terminal domains (in the truncated variant
MDTCS) would produce a similar activity enhancement as that
observed with VWF D4CK and 20E9 mAb. Indeed, both the WT
and GoF MDTCS variants were fully hyperactive, with activity
profiles indistinguishable from GoF ADAMTS13 (Fig. 3 A–C).
Moreover, truncation of ADAMTS13 after the TSP2-8 domains
(WTΔCUB1-2 variant) produced an enhancement similar to that
seen in WTMDTCS (Fig. 3D and F). Furthermore, reintroduction
of the isolated CUB1-2 domain fragment had a dose-dependent
inhibitory effect on both WT MDTCS and WTΔCUB1-2, reducing
activity similar to that of WT ADAMTS13 (Fig. 3 A and D). In
contrast, C-terminal truncation of GoF ADAMTS13 had no in-
fluence on its activity, and addition of the CUB1-2 domain frag-
ment was ineffective even at high concentrations (Figs. 3 B and E).
A CUB–Spacer Domain Binding Interaction. We developed a re-
ciprocal coimmunoprecipitation (co-IP) experiment to directly
analyze any CUB–spacer domain interaction. WT MDTCS and
the CUB1-2 domain fragment bound in solution and remained in
complex when either fragment was pulled down specifically by the
mAb. As a result, both fragments were detected in immunopre-
cipitation (IP) eluates and depleted from solution (Fig. 4A). In
contrast, when GoF MDTCS and CUB1-2 were incubated, only
the fragment being pulled down by its corresponding mAb was
detected in the eluate, with the other fragment remaining in so-
lution. Given that GoF MDTCS differs fromWTMDTCS only in
terms of spacer domain substitutions, this finding strongly suggests
the spacer domain as the site of CUB domain binding to MDTCS.
MDTCS-CUB co-IP performed over a range of MDTCS con-
centrations yielded KD(APP) values of ∼40 nM for the binding of
CUB1-2 and WT MDTCS (Fig. 4B). Minimal binding was ob-
served between CUB1-2 and GoF MDTCS.
ADAMTS13 Can Exist in a Closed or More Open Conformation. We
hypothesized that unfolding would result in an observable change
in the overall conformation of the full-length protein, and in-
vestigated this through transmission electron microscopy (TEM) of
negatively stained proteins (Fig. 5). Analysis of theWTADAMTS13
sample produced various monodisperse orientational particles
measuring between 12 and 16 nm, consistent with a protein
∼190 kDa in size. The main projection view had a clear compact,
globular conformation with an additional side “bulge” of pro-
jection density (Fig. 5A, panel 3); we assigned this as the closed
ADAMTS13 conformation. Examination of a similar number of
GoF ADAMTS13 particles revealed similar-sized particles, but
the projection averages produced were somewhat more linear
(Fig. 5B, panel 3), and the projection view with the side bulge was
absent. In addition, the projections were not as sharply delineated
as the ADAMTS13 samples; this feature, along with a different
population of particle projections, suggests that the complex has
adopted a more open organization with some local region of
protein in a flexible/unstructured conformation (Fig. 5, end panel).
Fig. 1. The increased VWF115 binding affinity and proteolytic activity of GoF
ADAMTS13. (A) initial rates of substrate proteolysis were used to determine
kcat and Km values (listed in Table 1). (B) The increased substrate recognition
suggested by the lower Km value of the GoF ADAMTS13 variant was confirmed
by an equilibrium plate-binding assay. (C–E) A twofold reduction in KD(APP) was
confirmed by SPR using both steady-state (C) and global fit (D and E) anal-
yses. The results are representative of three independent experiments.
Table 1. Activity and VWF115 binding affinity of ADAMTS13 variants
VWF115 proteolysis
VWF115 binding
Plate binding,
KD(APP), nM
SPR global fitting
SPR RUmax,
KD, nMVariant kcat, s
−1 Km, μM
kcat/Km,
105 M−1 s−1
kcat/Km(Time course),
105 M−1 s−1 ka, 10
4 M−1 s-1 kd, 10
−3 s−1 KD, nM
WT ADAMTS13 0.71 ± 0.09 1.54 ± 0.20 4.1 ± 0.5 5.5 ± 0.7 26.4 ± 3.0 3.72 ± 0.16 2.58 ± 0.01 72.3 ± 1.3 69.8 ± 6.2
GoF ADAMTS13 0.62 ± 0.02 0.86 ± 0.07* 8.3 ± 0.7* 10.4 ± 0.3* 11.5 ± 1.4* 6.82 ± 0.19* 2.64 ± 0.01 38.5 ± 1.2* 35.8 ± 2.6*
The activities of ADAMTS13 variants were determined by kinetic analysis of the initial rates of VWF115 proteolysis. The binding between VWF115 and
ADAMTS13 variants were determined by plate binding assays (KD(APP)), global fit SPR analysis (ka, kd, and KD), and steady-state SPR analysis (KD, RUmax plot).
Mean values ± SEM are based on three independent experiments.
*P < 0.05, t test.
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WT ADAMTS13 Conformational Activation Reveals Its Cryptic TTP
Autoantibody Binding Epitopes. WT ADAMTS13 was inhibited
by TTP patient autoantibodies and the single TTP patient-
derived II-1 mAb (28) in FRETS-VWF73 assays (Fig. 6A); how-
ever, despite the addition of a large excess of these antibodies to
activity assays, ADAMTS13 was inhibited by only 60%, compared
with 95% inhibition of MDTCS by the same TTP aAb (Fig. 6C).
This finding suggests that in its closed and relatively inactive state,
WT ADAMTS13 might not be readily recognized by these anti-
bodies. This was confirmed by IP of WT ADAMTS13 by the II-1
mAb covalently linked to magnetic beads. When converted to its
open conformation using the activating 20E9 mAb (Fig. 6D) or
VWF D4CK fragment (Fig. 6E), recognition of WT ADAMTS13
increased dramatically. The spacer domain mutations in GoF
ADAMTS13 have been shown to abolish this antigenicity (Fig.
6B); this was confirmed in this study by both FRET and IP assays
(Fig. 6 D and E).
Discussion
The concept of conformational activation of ADAMTS13 has
been alluded to previously as a possible explanation for the
suggested conflicting roles of the CUB domains (24, 29). Here we
present results indicating that ADAMTS13 naturally adopts
a folded or closed conformation, with folding mediated through
an interaction between the C-terminal CUB domains and the
more central spacer domain. The importance of this folding is
suggested by the known functional importance of the spacer do-
main, which serves as a critical exosite that interacts with a cryptic
binding site revealed on the VWF A2 domain as it unfolds (30).
This provides an essential localizing mechanism that helps ori-
entate the ADAMTS13 protease domain within reach of the
VWF scissile bond. A consequence of the folded conformation of
ADAMTS13 is that the important spacer domain exosite is only
partially available and requires full exposure to enable efficient
proteolysis of VWF.
It is now established that ADAMTS13 can interact with globular
VWF through recognition of its surface-exposed C-terminal
domain, D4CK, by the TSP-CUB domain region of ADAMTS13
(12, 13). This binding interaction has been considered a positioning
Fig. 2. WT ADAMTS13 activity can be enhanced by the addition of a VWF
D4CK domain fragment or addition of an activating mAb targeting the CUB2
domain. (A–C) The effect of the VWF D4CK domain fragment on ADAMTS13
activity was determined by a FRETS-VWF73 assay. GoF ADAMTS13 activity was
more than twofold greater than WT ADAMTS13 activity (P < 0.05), and was
not further increased by VWF D4CK. (D–F) The effect of the activating mAb
was assessed in the same manner. The antibody elicited a greater than
twofold increase in activity of the WT (P < 0.05), but had no effect on the
already hyperactive GoF variant. Results are presented as mean ± SEM (n = 3).
Fig. 3. WT ADAMTS13 hyperactivity resulting from C-terminal truncation
can be inhibited by the CUB1-2 domains. (A–C) The activity of WT and GoF
MDTCS variants was determined by a FRETS-VWF73 assay. Both enzymes
exhibited hyperactivity compared with WT ADAMTS13 (P < 0.05). WT MDTCS
activity can be inhibited by the addition of CUB1-2 domain fragment;
however, the fragment had no significant effect on GoF MDTCS. (D–F)
Specific removal of the CUB-domains from both WT and GoF ADAMTS13 also
resulted in a greater than twofold increase in activity (P < 0.05). The CUB1-2
domain fragment exhibited inhibitory activity when added to WTΔCUB1-2
(P < 0.05). Results are presented as mean ± SEM (n = 3).
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one, enabling a small amount of ADAMTS13 to associate reversibly
with VWF in its globular conformation, pending unfolding of VWF
(13); however, we now present evidence that the VWF D4CK
fragment can increase the activity of ADAMTS13 in a FRETS-
VWF73 assay. Thus, we suggest that on binding to the VWFD4CK
domains, ADAMTS13 unfolds to fully expose its cryptic spacer
domain exosite. Once unfolded, the spacer domain can directly
contact its VWF A2 complementary interaction site and enhance
the cleavage process.
An interaction between the spacer and CUB domains of
ADAMTS13 is supported by the results of addition of activating
mAb, as well as activity and binding assays of C-terminal trun-
cated WT ADAMTS13 in the presence of isolated CUB frag-
ments. Regarding the activating mAb, we have shown that 20E9
mAb, an antibody that recognizes the CUB2 domain region of
ADAMTS13, can increase the activity of WT ADAMTS13. In
FRETS-VWF73 assays, isolated CUB fragments inhibited the
proteolytic activities of both WT MDTCS and WTΔCUB1-2
truncation variants. Furthermore, in solution binding pulldown
experiments, we found that CUB fragments can directly bind to
these derivatives, with an estimated affinity of ∼40 nM. More-
over, the isolated CUB domain fragments inhibited WTΔCUB1-2,
which retains its TSP domains, suggesting that the CUB-binding
site on the spacer domain was not introduced by complete deletion
of these C-terminal domains.
Additional evidence for conformational activation of ADAMTS13
comes from our characterization of GoF ADAMTS13. This var-
iant was found to have an enhanced association rate with VWF
Fig. 4. The CUB1-2 domain fragment binds to WT MDTCS through the spacer domain. (A) MDTCS (filled arrowhead) and CUB1-2 (open arrowheads; present
also as a partially cleaved, faster mobility fragment) were immunoprecipitated using protein G beads coupled to the indicated mAb (3H9, directed to the
protease domain, or 20E9, directed to the CUB2 domain). The MDTCS and CUB fragments present in solution pre-IP and post-IP, along with bound proteins
after elution, were detected by polyclonal anti-ADAMTS13 Western blot analysis. Co-IP of WT MDTCS with CUB1-2 was evident under both experimental
conditions, but binding of GoF MDTCS was not apparent. MDTCS and CUB1-2 were also incubated with an isotype control IgG (15D7 mAb). (B) Affinity
between the CUB and spacer domains was determined by IP using magnetic beads coated with 20E9 mAb complexed to the CUB1-2 domain fragment.
Fig. 5. TEM analysis of WT ADAMTS13 (A) and GoF ADAMTS13 (B). Shown are representative examples of negatively stained TEM fields of view, individual
particles selected for analysis, and the results of multistatistical reference-free class averaging. (Scale bars: 50 nm.) (C) Schematic representation of the
proposed conformational change on activation, consistent with the existence of an interaction between the CUB domains (C1 and C2) and spacer domain (S),
shielding the VWF A2 domain-binding exosites.
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fragments, leading to an ∼2- to 2.5-fold overall enhanced cleav-
age of the scissile bond. The properties of this variant might arise
in part because of an increased molecular recognition of its
substrate induced by the five substitution mutations introduced in
the spacer domain. Alternatively, the enhanced activities also could
arise from disruption of the CUB–spacer domain interaction in this
variant by the introduced spacer domain substitution mutations.
We propose that this variant adopts a native unfolded conforma-
tion and thus is essentially preactivated. Support for this idea is
provided by its enhanced association rate with VWF115 and by
failure of 20E9 activating antibodies to enhance activity of the
variant. It is again interesting that pulldown experiments with
GoF MDTCS showed no binding of the isolated CUB1-2 domain
fragment. Moreover, the lack of inhibition in FRETS-VWF73
assay by the CUB domain fragment of GoF MDTCS and
GoFΔCUB1-2 truncation variants provides further support for the
lack of a masking interaction by the CUB domains and hence a
preactivation state. Based on our TEM experiments, we visualize
WT ADAMTS13 as a globular molecule, with GoF ADAMTS13
suggested to be less compact.
A potential advantage of conformational activation of
ADAMTS13 is that localization of the activated form of the pro-
tease will occur on the surface of its substrate, VWF. Conceivably,
this might offer a protective mechanism, particularly given that
ADAMTS13 is known to be susceptible to cleavage by several
coagulation proteases (31, 32). Conformational activation also can
have untoward consequences, however. Autoantibodies against
ADAMTS13 are known to cause or predispose to acquired TTP
(33). The trigger factors that initiate the autoimmune response
have yet to be fully delineated. It is interesting that the majority
of patients with TTP have autoantibodies directed to the
ADAMTS13 spacer domain (19, 34, 35); we propose that this is
because this domain is naturally cryptic, shielded by the CUB do-
mains. During the process of ADAMTS13 activation, the cryptic
epitopes are revealed and might be recognized as foreign during
a concurrent immune activation. Support for this concept is
provided by the increased recognition of WT ADAMTS13 spacer
domain by the patient-derived II-1 mAb in the presence of the
activating 20E9 antibody or VWF D4CK fragment. Consequently,
our results on the conformational activation of ADAMTS13
provide insights into both the proteolytic process by which
ADAMTS13 recognizes VWF and the mechanism of autoanti-
body formation in TTP.
Experimental Procedures
Production of Recombinant ADAMTS13 and VWF Fragments. Recombinant
human ADAMTS13 with a C-terminal Myc/His6 tag in pCDNA3.1 (31) was used
to generate GoF ADAMTS13 (R568K/F592Y/R660K/Y661F/Y665F) by sequen-
tial site-directed mutagenesis. The same mutagenesis primers were also used
to introduce the GoF mutations into WT MDTCS-Myc/His6. The truncated
variants WTΔCUB1-2 and GoFΔCUB1-2 (ADAMTS13 residues 1–1190) and the
CUB1-2 domain fragment (ADAMTS13 residues 1191–1427) were generated
by inverse PCR using the full-length ADAMTS13 constructs. All ADAMTS13
variants and fragments were expressed in HEK293S cells, purified, and
quantified using in-house ELISA as described previously (36). For electron
microscopy, ADAMTS13 was further purified to homogeneity by gel filtra-
tion using a Superose 12 10/300 GL column (GE Healthcare).
The VWF A2 domain fragment VWF115 (VWF residues 1554–1668) was
expressed and purified as described previously (31). The VWF D4CK domain
fragment (VWF residues 1874–2813) in the vector pcDNA 3.1/His was tran-
siently expressed in HEK293S, purified by FPLC, and quantified by ELISA (12).
Production and Characterization of Anti-ADAMTS13 mAb 20E9. The 20E9 mAb
was one of 30 anti-ADAMTS13 mAbs obtained after immunization of WT
BALB/c mice with recombinant WT ADAMTS13, followed by fusion of their
spleen cells with Sp2/0 myeloma cells. The epitope of mAb 20E9 is situated in
the CUB2 domain as determined by epitope mapping using a series of
ADAMTS13 variants in which all domains were individually deleted.
TTP Patient IgG Preparation. Total IgG was isolated from the presentation
plasma sample of a TTP patient with high-titer anti-ADAMTS13 IgG directed
against the spacer domain, using melon gel spin columns (Thermo Scientific).
Ethical approval for the use of the sample was obtained from the local Re-
search Ethics Committee (reference 08/H0716/72).
ADAMTS13 Activity Assays. Recombinant VWF A2 domain fragments VWF115
(VWF residues 1554–1668) and FRETS-VWF73 (VWF residues 1596–1668), which
span the ADAMTS13 cleavage site and spacer domain-binding exosites, were
used as proteolytic substrates to determine the activity of ADAMTS13 and its
variants. Cleavage of VWF115 by ADAMTS13 was carried out as described
Fig. 6. WT ADAMTS13 recognition and inhibition by TTP autoantibodies is
enhanced on activation by the anti-CUB 20E9 mAb. (A) Proteolysis of the
FRETS-VWF73 substrate by WT ADAMTS13 was markedly decreased (P < 0.05)
when the enzyme was preincubated with either TTP patient total IgG or TTP
patient-derived II-1 mAb. (B and C) GoF ADAMTS13 activity in FRETS-VWF73
assays (B) was increased twofold compared with WT ADAMTS13 activity (C);
however, it was not impaired by either antibody. IP of ADAMTS13 in solution
using the II-1 mAb covalently coupled to magnetic beads suggested that WT
ADAMTS13 is not efficiently recognized. (D and E) Pretreatment of WT
ADAMTS13 with the activating anti-CUB 20E9 mAb (D) or the VWF D4CK
domain fragment (E) greatly increased its capture by the beads.
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previously (18). For FRETS-VWF73 assays, ADAMTS13, MDTCS, and ΔCUB1-2
variants (WT and GoF) were diluted to 0.3 nM in reaction buffer (5 mM Bis-Tris
pH 6.0, 25 mM CaCl2, and 0.005% Tween-20) in white 96-well plates (Nunc).
Purified CUB1-2 domain fragment, VWF D4CK, 20E9 mAb, II-1 mAb, or TTP
patient IgG was added, followed by preincubation for 45 min at 37 °C. The
reaction was initiated by the addition of an equal volume of 4 μM FRETS-
VWF73 substrate (Peptanova). Fluorescence (excitation, 340 nm; emission, 460 nm)
was measured at 30 °C at 1-min intervals for 1 h using a Fluostar Omega plate
reader (BMG Labtech). Results were normalized to WT ADAMTS13 activity to
allow cross-comparison of any changes.
Equilibrium Plate-Binding Assay and Surface Plasmon Resonance. The binding
of VWF115 to ADAMTS13 was determined by an equilibrium plate-binding
assay (12, 18) and by SPR using a BIAcore T100 protein interaction analysis
system, as described previously (12).
Co-IP Analysis of the CUB–MDTCS Interaction. Samples containing 40 nMMDTCS
(WT or GoF) in the absence and presence of 40 nM CUB1-2 fragment were
immunoprecipitated using protein G Dynabeads (Invitrogen) coupled to the
3H9 mAb against the ADAMTS13 metalloprotease domain (32, 37), the 20E9
mAb directed against the ADAMTS13 CUB domains, or the IgG isotype con-
trol 15D7 mAb (38). Beads were washed, and bound protein was eluted in 1×
LDS loading buffer at 70 °C for 10 min. Inputs (pre-IP), flow-through (post-IP),
and bound protein in eluates were analyzed by SDS/PAGE and anti-
ADAMTS13 Western blot analysis.
For CUB-MDTCS affinity determination, blocked and 20E9 mAb-coated
Dynabeads were preincubated with 100 nM CUB1-2 domain fragment and
used to immunoprecipitate MDTCS (WT or GoF) at increasing concentrations
(5–200 nM). Bound MDTCS was eluted in 20 mM Tris pH 7.4 and 1 M NaCl.
Bound and free MDTCS concentrations were determined by in-house ELISA,
and KD values were determined by fitting data to a one-site binding hy-
perbola using GraphPad Prism 4 software.
TTP Autoantibody Binding. The TTP patient-derived II-1 mAb (28) (kindly pro-
vided by Prof J. Voorberg and Dr. N. Sorvillo) was covalently coupled to M280
tosylactivated Dynabeads (Invitrogen) following the manufacturer’s instruc-
tions. The coupled beads were added to 40 nM ADAMTS13 (WT or GoF) and
preincubated for 1 h at 37 °C in the absence and presence of 4 μg of 20E9
mAb. After a 4-h incubation, the beads were washed, and bound protein was
eluted in LDS loading buffer. Inputs (pre-IP), flow through (post-IP), and elu-
ates were analyzed by SDS/PAGE and anti-ADAMTS13 Western blot analysis.
TEM. Fully purified samples of ADAMTS13 variants (10 μL of ∼10 μg/mL) in
20 mM Tris pH 7.8, 150 mM NaCl, and 5 mM CaCl2 were applied to glow-dis-
charged continuous carbon-coated 400-mesh copper grids (TAAB Laboratories)
for 1 min. Excess sample was blotted using Whatman paper, and the protein
was negatively stained by the addition of 10 μL of 5% (wt/vol) uranyl acetate
for 1 min. Images were acquired at a nominal magnification of 39,000× using
a Philips Tecnai30 Polara FEG electron microscope operating at 200 kV low-
dose mode, and recorded on a Gatan 4K charge-coupled device camera.
Image analysis of the recorded TEM DM3 data files was performed using
EMAN2 (blake.bcm.edu/emanwiki/EMAN2). Equivalent datasets of ∼6,000 par-
ticles were boxed out of images using semiautomated swarm picking; any ag-
gregated or overlapping data were discarded. Data were CTF-corrected, and the
dataset underwent multistatistical reference-free 2D classification. Data were
automasked, amaximum shift of five pixels was applied, and the cross-correlation
coefficient served as the main comparator. Projection averages of each particle
orientations were selected, and a low-pass Gaussian filter (20 Å) was applied.
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